METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Clinical trials for METASTATIC CASTRATION RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Long-Lasting injection tested for Tough-to-Treat prostate cancer
Disease control Recruiting nowThis study is testing a new long-acting injection called PRL-02 for men with advanced prostate cancer that has returned or stopped responding to prior treatment. The main goals are to find a safe and tolerable dose and to see how well the body handles the drug. Men in the study w…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Apr 01, 2026 18:41 UTC
-
Shocking cancer cells: high testosterone jolt may make prostate cancer drugs work better
Disease control Recruiting nowThis study is testing a new approach for men with advanced prostate cancer that has spread. Researchers want to see if giving cycles of very high testosterone followed by a drug that blocks testosterone (darolutamide) can control the cancer longer and cause fewer side effects tha…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New hope for tough prostate cancer cases in early drug trial
Disease control Recruiting nowThis early-stage study is testing a new drug called BMS-986460 in men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. The main goal is to check the drug's safety and side effects in about 140 participants. Researchers will also…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
First patients receive experimental cancer drug in groundbreaking safety trial
Disease control Recruiting nowThis is the first human trial of an experimental drug called DS9051b for people with advanced adrenal gland cancer or metastatic prostate cancer that has stopped responding to standard hormone treatments. The main goal is to find a safe dose and understand the drug's side effects…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
Radioactive drug trial offers new hope for advanced prostate cancer
Disease control Recruiting nowThis is a first-in-human study testing a new radioactive drug called AZD2284 in men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The main goal is to find a safe and tolerable dose. Researchers will also use imaging to see how t…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New hope for advanced breast cancer patients in early drug trial
Disease control Recruiting nowThis early-stage study is testing a new drug called GVV858, both by itself and combined with standard hormone therapies, for people with advanced breast cancer and other solid tumors. The main goals are to find a safe dose and see how well the body handles the drug. Researchers w…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New Two-Drug attack on tough prostate cancer
Disease control Recruiting nowThis study is testing whether adding an experimental drug called SX-682 to a standard prostate cancer drug (enzalutamide) can help men whose cancer has spread and stopped responding to other hormone therapies. The goal is to see if this combination can control the cancer's growth…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Syntrix Biosystems, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New Two-Drug attack on tough prostate cancer
Disease control Recruiting nowThis study is testing if adding a second chemotherapy drug, carboplatin, to the standard drug docetaxel can help men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to see if this combination can slow the cancer's growth and help patients…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Apr 01, 2026 14:40 UTC
-
New hope for tough prostate cancer: first human trial begins
Disease control Recruiting nowThis is the first study in people testing a new drug called ABBV-969 for men with advanced prostate cancer that has spread and no longer responds to standard hormone-blocking treatments. The main goals are to find a safe dose, see how the body processes the drug, and check for ea…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New prostate cancer shot tested as alternative to daily pills
Disease control Recruiting nowThis study is testing a new injectable form of a prostate cancer hormone therapy called ASP5541. It aims to see if this injection, given every 12 weeks, works as well or better than the standard daily pill version and if it causes fewer side effects. The trial will enroll about 2…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New drug duo tested in fight against spreading prostate cancer
Disease control Recruiting nowThis is an early-stage trial testing the safety and initial effectiveness of combining two drugs, valemetostat and darolutamide, for men with metastatic castration-resistant prostate cancer (mCRPC). The study will enroll about 60 men whose cancer has spread and is no longer respo…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New prostate cancer drug begins first human testing
Disease control Recruiting nowThis is the first study in people to test the safety and side effects of a new oral drug called HRS-5041. It will involve about 25 men with advanced prostate cancer that has spread and no longer responds to standard hormone treatments. The main goal is to find a safe dose and see…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Atridia Pty Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New shot targets tough prostate cancer
Disease control Recruiting nowThis study is testing if a drug called bortezomib, given as an injection, can help control advanced prostate cancer that has stopped responding to standard hormone treatments and has a specific genetic change called PTEN deletion. Researchers want to see if the treatment causes a…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
Targeted radiation tested for prostate cancer patients with dangerous blood counts
Disease control Recruiting nowThis study is testing a targeted radiation drug called 177Lu-PSMA-617 in men with advanced prostate cancer that has spread to the bone marrow and caused low blood cell counts. The main goal is to see if the treatment is safe and effective for this specific group of patients who o…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Experimental radiation therapy targets advanced prostate cancer
Disease control Recruiting nowThis early study is testing two new radioactive drugs for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. Researchers will give patients a single injection and closely monitor them to check safety, measure how the drug trav…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: EARLY_PHASE1 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New hope for men with Tough-to-Treat prostate cancer
Disease control Recruiting nowThis study is testing whether a new drug called BMS-986365 works better and is safer than current standard treatments for advanced prostate cancer that has spread and no longer responds to hormone-blocking drugs. It will involve about 960 men whose cancer has progressed after ini…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New prostate cancer injection enters first human tests in china
Disease control Recruiting nowThis early-stage study aims to check the safety and measure how a new drug called ASP5541 moves through the body in Chinese men with advanced prostate cancer. The drug is given as a hip muscle injection alongside standard hormone therapy and prednisone. The main goals are to unde…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New Two-Pronged attack tested for Tough-to-Treat prostate cancer
Disease control Recruiting nowThis study is testing a new combination treatment for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapies. It combines a targeted radiation drug that seeks out and destroys prostate cancer cells with an immunotherapy drug de…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New hope for men with Tough-to-Treat prostate cancer
Disease control Recruiting nowThis study is testing a new targeted radiation drug called FPI-2265 for men with advanced prostate cancer that has spread and is no longer responding to standard hormone treatments. The goal is to find the safest and most effective dose and schedule for this new therapy. The stud…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Second shot at hope: retrying Cancer-Killing radiation for prostate patients
Disease control Recruiting nowThis study is testing whether giving a second course of a targeted radiation drug called [177Lu]Lu-PSMA-617 can help men with advanced prostate cancer that has started growing again. The treatment specifically targets prostate cancer cells. The trial will enroll 58 men whose canc…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope for tough prostate cancer: experimental drug takes on standard therapies
Disease control Recruiting nowThis study aims to see if a new drug called xaluritamig helps men with advanced prostate cancer live longer than current standard treatments. It will enroll about 675 men whose cancer has spread and stopped responding to prior hormone therapy and one round of chemotherapy. Partic…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New cancer drug targets genetic weakness in advanced tumors
Disease control Recruiting nowThis early-stage trial is testing a new drug called FOG-001 for people with advanced or spreading cancers that have specific genetic mutations. Researchers want to find the safest dose and see if the drug can shrink tumors or slow cancer growth. The study will include 575 partici…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Parabilis Medicines, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New hope for advanced prostate cancer patients in major drug trial
Disease control Recruiting nowThis study is testing whether adding an experimental drug called xaluritamig to standard hormone therapy helps men with advanced prostate cancer live longer. It will compare this combination against current standard treatments in 750 men whose cancer has spread and stopped respon…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Radioactive drug tested to target advanced prostate cancer
Disease control Recruiting nowThis early-stage study is testing a radioactive drug called AAA617 for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The main goals are to see where the radiation goes in the body, measure how much radiation organs and tumor…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Tracking a new weapon against advanced prostate cancer in real patients
Disease control Recruiting nowThis study aims to understand how well a targeted radiation drug works for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. Researchers will follow 300 patients in real-world clinics for up to 18 months after treatment to see h…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New hope for Tough-to-Treat prostate cancer: major trial tests multiple drug combos
Disease control Recruiting nowThis study is testing the safety and effectiveness of several different drug combinations, all built around an immunotherapy drug called pembrolizumab, for men with advanced prostate cancer that has spread and is no longer responding to standard hormone treatments. It will enroll…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
Scientists test shock therapy: combining cancer vaccine with testosterone to fight advanced prostate cancer
Disease control Recruiting nowThis study is testing whether adding testosterone injections to an approved prostate cancer vaccine (Sipuleucel-T) can boost the immune system's attack on cancer cells. It will involve 26 men whose prostate cancer has spread and stopped responding to standard hormone-blocking tre…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
Scientists flip the script: using testosterone to fight prostate cancer
Disease control Recruiting nowThis study is testing a two-step treatment for advanced prostate cancer that has become resistant to standard hormone therapy. First, men receive high-dose testosterone, followed by a targeted radiation drug that seeks out and destroys cancer cells. The goal is to see if this com…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
New weapon against aggressive prostate cancer enters human testing
Disease control Recruiting nowThis study is testing a new drug called FG-3246 for men with metastatic prostate cancer that has stopped responding to standard hormone treatments. The trial aims to find the best dose and see how well the drug works at slowing cancer growth and controlling symptoms. About 75 par…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Kyntra Bio • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
New hope for men battling aggressive prostate cancer
Disease control Recruiting nowThis is the first study in people to test a new drug called JANX007 for men with advanced prostate cancer that has spread and no longer responds to standard hormone-blocking treatments. The main goals are to find a safe dose and see how the body handles the drug. Researchers will…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Janux Therapeutics • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
Shock therapy? giving testosterone to fight prostate cancer
Disease control Recruiting nowThis study is testing a two-step treatment for men whose prostate cancer has spread and stopped responding to standard hormone-blocking therapies. First, patients receive high-dose testosterone combined with an experimental drug called ZEN-3694. If the cancer progresses, they the…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New drug trial offers hope for men with aggressive prostate cancer
Disease control Recruiting nowThis is the first study in people testing a new drug called KTX2001 for advanced prostate cancer that has spread and stopped responding to standard hormone treatments. Researchers will give the drug alone and combined with an existing medication (darolutamide) to about 144 men to…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Experimental cell therapy tested in men with untreatable prostate cancer
Disease control Recruiting nowThis is the first human study of an experimental cell therapy called A-CAR032 for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. The trial will test the safety of different doses and see if the therapy can shrink tumors. I…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Shanghai AbelZeta Ltd. • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New hope for tough prostate cancer: experimental therapy targets resistant tumors
Disease control Recruiting nowThis study is testing a new immunotherapy called SV-102 for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. Researchers will give the treatment directly into tumors to find the safest and most effective dose while checking …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Syncromune, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New hope pill tested for tough prostate cancer cases
Disease control Recruiting nowThis study is testing whether a daily pill called XL092 can help control advanced prostate cancer that has continued to grow despite previous radiation treatment. Researchers will check if participants' cancer has stopped progressing after 16 weeks of treatment and monitor side e…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New drug combo tested to control advanced prostate cancer
Disease control Recruiting nowThis study is testing whether a new two-drug combination (inavolisib plus enzalutamide) works better and is safer than standard treatments for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It will enroll about 100 participants whose …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
Targeted radiation zaps prostate cancer in new trial
Disease control Recruiting nowThis study is testing a new radioactive drug called [²¹²Pb]Pb-ADVC001 for men with prostate cancer that has spread. The first part aims to find the safest and most effective dose. The second part will see how well that dose works to control the cancer in different groups of patie…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: AdvanCell Pty Limited • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
New immune weapons target advanced prostate cancer
Disease control Recruiting nowThis study is testing new immunotherapy drugs for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. The goal is to find safe doses and see if these drugs, which aim to activate the body's own immune cells to attack cancer, ca…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
Targeted radiation zaps advanced prostate cancer in new trial
Disease control Recruiting nowThis study is testing a new radioactive drug called lutetium (177Lu) rhPSMA-10.1 for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapies. The goal is to find a safe and effective dose that can shrink tumors by delivering rad…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Blue Earth Therapeutics Ltd • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
Doctors track Real-World results of new prostate cancer treatment
Disease control Recruiting nowThis study is observing how well the approved prostate cancer drug Pluvicto works and what side effects patients experience in real-world medical practice in South Korea. It will follow about 278 adult men with advanced prostate cancer that has spread and stopped responding to ho…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
Experimental immune therapy offers hope for men with aggressive prostate cancer
Disease control Recruiting nowThis early-stage trial is testing a new type of immune cell therapy for men with advanced prostate cancer that has spread to bones and no longer responds to standard hormone treatments. Doctors will collect patients' own immune cells, modify them in a lab to better target prostat…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
Radioactive hope: first human test for tough prostate cancer
Disease control Recruiting nowThis is the first-ever study in people to test a new radioactive drug called [225Ac]Ac-FL-020 for men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The main goals are to find a safe dose and see how the body handles the drug. Re…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Full-Life Technologies GmbH • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
New oral drug trial offers hope for advanced prostate cancer patients
Disease control Recruiting nowThis early-stage study is testing a new oral medication called HP518 for men with advanced prostate cancer that has spread and stopped responding to standard treatments. The trial aims to find the safest and most effective dose while checking if the drug can reduce cancer markers…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Hinova Pharmaceuticals Inc. • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
Scientists test Two-Drug punch for tough prostate cancer
Disease control Recruiting nowThis study is testing a two-step treatment for advanced prostate cancer that has spread and stopped responding to standard hormone therapies and chemotherapy. First, patients take a pill (abemaciclib) for two weeks, aiming to make cancer cells more visible. Then, they receive a t…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Vadim S Koshkin • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
Major trial aims to slow deadly prostate cancer spread
Disease control Recruiting nowThis large, late-stage study is testing whether adding a new drug called mevrometostat to a standard prostate cancer drug (enzalutamide) works better than the standard drug alone. It will involve 900 men with advanced prostate cancer that has spread and stopped responding to horm…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC
-
Double attack on prostate cancer: new combo trial seeks to halt spread
Disease control Recruiting nowThis early-stage trial is testing the safety and initial effectiveness of combining two treatments for advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The combination pairs a targeted drug (cabozantinib) with a radioactive therapy (177…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated Mar 03, 2026 14:06 UTC
-
New scan aims to sharpen the picture of prostate cancer
Diagnosis Recruiting nowThis study is testing a new type of imaging scan to see if it can clearly show where prostate cancer has spread in the body. It will compare this new scan to another type of scan that is already used. The goal is to see if the new scan is a good tool for patients who are schedule…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Diagnosis
Last updated Mar 27, 2026 12:38 UTC
-
New scan could reveal if cancer immunotherapy is working
Knowledge-focused Recruiting nowThis study is testing a new type of PET scan that uses a special tracer called 64Cu-GRIP B. The goal is to see if this scan can safely detect a marker of immune system activity (granzyme B) in tumors of patients with advanced cancers, including prostate, kidney, and bladder cance…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Rahul Aggarwal • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:11 UTC
-
French doctors track Real-World results of prostate cancer drug
Knowledge-focused Recruiting nowThis study is observing 300 men in France with advanced prostate cancer who are taking the medication olaparib in real-world settings. Researchers will track how long patients stay on the treatment, how well it works, and what side effects occur. The goal is to gather practical i…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:11 UTC
-
Tracking real results: how men fare on advanced prostate cancer combo
Knowledge-focused Recruiting nowThis study observes 250 men with advanced prostate cancer who are already receiving a specific two-drug combination (olaparib + abiraterone) in real-world clinics. The goal is to understand how long patients stay on this treatment and what happens afterward, without changing thei…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:32 UTC
-
Tracking life quality in men battling advanced prostate cancer
Knowledge-focused Recruiting nowThis study aims to understand how lutetium treatment affects daily life and quality of life in men with advanced prostate cancer that has spread and stopped responding to hormone therapy. Researchers will follow 500 patients receiving this approved treatment in real-world setting…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Mar 24, 2026 12:02 UTC
-
Massive 5,000-Patient study maps prostate Cancer's Real-World journey
Knowledge-focused Recruiting nowThis study is a large registry that will track 5,000 men in Germany with recurrent or metastatic prostate cancer. Its purpose is to observe and document the real-world treatments doctors choose, how the disease progresses, and how patients' quality of life is affected. It does no…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Sponsor: UroTrials Company (GmbH) • Aim: Knowledge-focused
Last updated Feb 25, 2026 15:07 UTC